Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (added medications) |
m (added medications) |
||
| Line 19: | Line 19: | ||
*[[Antithrombin III (Thrombate III)]] | *[[Antithrombin III (Thrombate III)]] | ||
*[[Antithymocyte globulin (ATG)]] | *[[Antithymocyte globulin (ATG)]] | ||
| + | *[[Argatroban]] | ||
*[[Arsenic trioxide (Trisenox)]] | *[[Arsenic trioxide (Trisenox)]] | ||
*[[Asparaginase (Elspar)]] | *[[Asparaginase (Elspar)]] | ||
*[[Asparaginase Erwinia chrysanthemi (Erwinaze)]] '''FDA approved 11/18/2011''' | *[[Asparaginase Erwinia chrysanthemi (Erwinaze)]] '''FDA approved 11/18/2011''' | ||
| + | *[[Aspirin]] | ||
*[[Atovaquone (Mepron)]] | *[[Atovaquone (Mepron)]] | ||
*[[Axitinib (Inlyta)]] '''FDA approved 1/27/2012''' | *[[Axitinib (Inlyta)]] '''FDA approved 1/27/2012''' | ||
| Line 32: | Line 34: | ||
*[[Bexarotene (Targretin)]] | *[[Bexarotene (Targretin)]] | ||
*[[Bicalutamide (Casodex)]] | *[[Bicalutamide (Casodex)]] | ||
| + | *[[Bivalirudin (Angiomax)]] | ||
*[[BHQ880 (Anti-DKK1 Antibody)]] '''in clinical trials''' | *[[BHQ880 (Anti-DKK1 Antibody)]] '''in clinical trials''' | ||
*[[Bleomycin (Blenoxane)]] | *[[Bleomycin (Blenoxane)]] | ||
| Line 51: | Line 54: | ||
*[[Cladribine (Leustatin)]] | *[[Cladribine (Leustatin)]] | ||
*[[Clofarabine (Clolar)]] | *[[Clofarabine (Clolar)]] | ||
| + | *[[Clopidogrel (Plavix)]] | ||
*[[Crizotinib (Xalkori)]] | *[[Crizotinib (Xalkori)]] | ||
| + | *[[Cyanocobalamin (Vitamin B12)]] | ||
*[[Cyclophosphamide (Cytoxan)]] | *[[Cyclophosphamide (Cytoxan)]] | ||
| + | *[[Cyclosporine modified (Neoral)]] | ||
| + | *[[Cyclosporine non-modified (Sandimmune)]] | ||
*[[Cytarabine (Cytosar)]] | *[[Cytarabine (Cytosar)]] | ||
*[[Cytarabine liposomal (DepoCyt)]] | *[[Cytarabine liposomal (DepoCyt)]] | ||
| Line 61: | Line 68: | ||
*[[Dacarbazine (DTIC)]] | *[[Dacarbazine (DTIC)]] | ||
*[[Dactinomycin (Cosmegen)]] | *[[Dactinomycin (Cosmegen)]] | ||
| + | *[[Dalteparin (Fragmin)]] | ||
| + | *[[Darbepoetin alfa (Aranesp)]] | ||
*[[Dasatinib (Sprycel)]] | *[[Dasatinib (Sprycel)]] | ||
*[[Daunorubicin (Cerubidine)]] | *[[Daunorubicin (Cerubidine)]] | ||
| Line 83: | Line 92: | ||
*[[Elotuzumab (HuLuc63)]] '''in clinical trials''' | *[[Elotuzumab (HuLuc63)]] '''in clinical trials''' | ||
*[[Eltrombopag (Promacta)]] | *[[Eltrombopag (Promacta)]] | ||
| + | *[[Enoxaparin (Lovenox)]] | ||
*[[Epirubicin (Ellence)]] | *[[Epirubicin (Ellence)]] | ||
| + | *[[Epoetin alfa (Procrit)]] | ||
*[[Eribulin (Halaven)]] | *[[Eribulin (Halaven)]] | ||
*[[Erlotinib (Tarceva)]] | *[[Erlotinib (Tarceva)]] | ||
| Line 96: | Line 107: | ||
*[[Factor IX, human and recombinant (coagulation factor 9)]] | *[[Factor IX, human and recombinant (coagulation factor 9)]] | ||
*[[Factor XIII concentrate, human (Corifact)]] | *[[Factor XIII concentrate, human (Corifact)]] | ||
| + | *[[Ferric gluconate (Ferrlecit)]] | ||
| + | *[[Ferrous sulfate (Feosol)]] | ||
*[[Ferumoxytol (Feraheme)]] | *[[Ferumoxytol (Feraheme)]] | ||
*[[Filgrastim (Neupogen)]] | *[[Filgrastim (Neupogen)]] | ||
| Line 104: | Line 117: | ||
*[[Flutamide (Eulexin)]] | *[[Flutamide (Eulexin)]] | ||
*[[Folinic acid (Leucovorin)]] | *[[Folinic acid (Leucovorin)]] | ||
| + | *[[Fondaparinux (Arixtra)]] | ||
*[[Fulvestrant (Faslodex)]] | *[[Fulvestrant (Faslodex)]] | ||
| Line 117: | Line 131: | ||
==H== | ==H== | ||
*[[Hematopoetic progenitor cells, cord blood (Hemacord)]] - '''FDA approved 11/10/2011''' | *[[Hematopoetic progenitor cells, cord blood (Hemacord)]] - '''FDA approved 11/10/2011''' | ||
| + | *[[Heparin]] | ||
*[[Hydroxyurea (Hydrea)]] | *[[Hydroxyurea (Hydrea)]] | ||
| Line 130: | Line 145: | ||
*[[IPH 2101 (Anti-KIR)]] '''in clinical trials''' | *[[IPH 2101 (Anti-KIR)]] '''in clinical trials''' | ||
*[[Irinotecan (Camptosar)]] | *[[Irinotecan (Camptosar)]] | ||
| + | *[[Iron dextran (INFeD)]] | ||
| + | *[[Iron sucrose (Venofer)]] | ||
*[[Ixabepilone (Ixempra)]] | *[[Ixabepilone (Ixempra)]] | ||
| Line 135: | Line 152: | ||
*[[Lapatinib (Tykerb)]] | *[[Lapatinib (Tykerb)]] | ||
*[[Lenalidomide (Revlimid)]] | *[[Lenalidomide (Revlimid)]] | ||
| + | *[[Lepirudin (Refludan)]] | ||
*[[Letrozole (Femara)]] | *[[Letrozole (Femara)]] | ||
*[[Leuprolide (Lupron)]] | *[[Leuprolide (Lupron)]] | ||
| Line 149: | Line 167: | ||
*[[Mitotane (Lysodren)]] | *[[Mitotane (Lysodren)]] | ||
*[[Mitoxantrone (Novantrone)]] | *[[Mitoxantrone (Novantrone)]] | ||
| + | *[[Mycophenolate mofetil (CellCept)]] | ||
==N== | ==N== | ||
| Line 159: | Line 178: | ||
*[[Obinutuzumab (GA101)]] '''in clinical trials''' | *[[Obinutuzumab (GA101)]] '''in clinical trials''' | ||
*[[Octreotide (Sandostatin)]] | *[[Octreotide (Sandostatin)]] | ||
| − | *[[Ofatumumab ( | + | *[[Ofatumumab (Arzerra)]] |
*[[Olaparib (AZD-2281)]] '''in clinical trials''' | *[[Olaparib (AZD-2281)]] '''in clinical trials''' | ||
*[[Omacetaxine mepesuccinate (Omapro)]] '''in clinical trials''' | *[[Omacetaxine mepesuccinate (Omapro)]] '''in clinical trials''' | ||
| Line 168: | Line 187: | ||
*[[Paclitaxel (Taxol)]] | *[[Paclitaxel (Taxol)]] | ||
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] | *[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] | ||
| + | *[[Pamidronate (Aredia)]] | ||
*[[Panitumumab (Vectibix)]] | *[[Panitumumab (Vectibix)]] | ||
*[[Pazopanib (Votrient)]] | *[[Pazopanib (Votrient)]] | ||
| Line 178: | Line 198: | ||
*[[Pentostatin (Nipent)]] | *[[Pentostatin (Nipent)]] | ||
*[[Pertuzumab (Omnitarg)]] '''in clinical trials''' | *[[Pertuzumab (Omnitarg)]] '''in clinical trials''' | ||
| + | *[[Phytonadione (Vitamin K)]] | ||
*[[Plerixafor (Mozobil)]] | *[[Plerixafor (Mozobil)]] | ||
*[[Plicamycin (Mithracin)]] | *[[Plicamycin (Mithracin)]] | ||
| Line 191: | Line 212: | ||
*[[Regorafenib (BAY 73-4506)]] '''in clinical trials''' | *[[Regorafenib (BAY 73-4506)]] '''in clinical trials''' | ||
*[[Rituximab (Rituxan)]] | *[[Rituximab (Rituxan)]] | ||
| + | *[[Rivaroxaban (Xarelto)]] '''FDA approved 7/1/2011'' | ||
*[[Romidepsin (Istodax)]] | *[[Romidepsin (Istodax)]] | ||
*[[Romiplostim (Nplate)]] | *[[Romiplostim (Nplate)]] | ||
| − | *[[Ruxolitinib (Jakafi)]] | + | *[[Ruxolitinib (Jakafi)]] '''FDA approved 11/16/2011''' |
==S== | ==S== | ||
| Line 203: | Line 225: | ||
==T== | ==T== | ||
| + | *[[Tacrolimus (Prograf)]] | ||
*[[Tamoxifen (Nolvadex)]] | *[[Tamoxifen (Nolvadex)]] | ||
*[[Temozolomide (Temodar)]] | *[[Temozolomide (Temodar)]] | ||
| Line 235: | Line 258: | ||
*[[Von Willebrand Factor and factor VIII complex, human]] | *[[Von Willebrand Factor and factor VIII complex, human]] | ||
*[[Vorinostat (Zolinza)]] | *[[Vorinostat (Zolinza)]] | ||
| + | |||
| + | ==W== | ||
| + | *[[Warfarin (Coumadin)]] | ||
==Z== | ==Z== | ||
Revision as of 03:51, 13 March 2012
- List of chemotherapy regimens
- Vesicant & irritant chemotherapy
- Antiemetic support
- Steroid conversions
A
- Abiraterone (Zytiga) FDA approved 4/28/2011
- Afatinib (BIBW 2992) in clinical trials
- Aflibercept (Zaltrap) in clinical trials
- Aldesleukin (Proleukin)
- Alemtuzumab (Campath)
- All-trans retinoic acid (ATRA)
- Altretamine (Hexalen)
- AMG 386 in clinical trials
- Amifostine (Ethyol)
- Aminoglutethimide (Cytadren)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Antithrombin III (Thrombate III)
- Antithymocyte globulin (ATG)
- Argatroban
- Arsenic trioxide (Trisenox)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze) FDA approved 11/18/2011
- Aspirin
- Atovaquone (Mepron)
- Axitinib (Inlyta) FDA approved 1/27/2012
- Azacitidine (Vidaza)
B
- Bacillus Calmette-Guerin (BCG, TheraCys)
- Bendamustine (Treanda)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Bivalirudin (Angiomax)
- BHQ880 (Anti-DKK1 Antibody) in clinical trials
- Bleomycin (Blenoxane)
- Bortezomib (Velcade)
- Brentuximab vedotin (Adcetris) FDA approved 8/19/2011
- Busulfan (Myleran)
- Bosutinib (SKI-606) in clinical trials
C
- Cabazitaxel (Jevtana)
- Cabozantinib (XL184) in clinical trials
- Capecitabine (Xeloda)
- Carboplatin (Paraplatin)
- Carmustine (BiCNU)
- Catumaxomab (Removab) in US clinical trials
- Cetuximab (Erbitux)
- Chlorambucil (Leukeran)
- Cisplatin (Platinol)
- Cladribine (Leustatin)
- Clofarabine (Clolar)
- Clopidogrel (Plavix)
- Crizotinib (Xalkori)
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine modified (Neoral)
- Cyclosporine non-modified (Sandimmune)
- Cytarabine (Cytosar)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus (CMV) Human Immunoglobulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dacarbazine (DTIC)
- Dactinomycin (Cosmegen)
- Dalteparin (Fragmin)
- Darbepoetin alfa (Aranesp)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Deferasirox (Exjade)
- Deferiprone (Ferriprox) - FDA approved 10/14/2011
- Deferoxamine (Desferal)
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexamethasone (Decadron)
- Dexrazoxane (Zinecard)
- Docetaxel (Taxotere)
- Doxorubicin (Adriamycin)
- Doxorubicin liposomal (Doxil)
- Dutasteride (Avodart)
E
- Eculizumab (Soliris)
- Elotuzumab (HuLuc63) in clinical trials
- Eltrombopag (Promacta)
- Enoxaparin (Lovenox)
- Epirubicin (Ellence)
- Epoetin alfa (Procrit)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estramustine (Emcyt)
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human and recombinant (antihemophilic factor 8)
- Factor IX, human and recombinant (coagulation factor 9)
- Factor XIII concentrate, human (Corifact)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fludarabine (Fludara)
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Fondaparinux (Arixtra)
- Fulvestrant (Faslodex)
G
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemtuzumab ozogamicin (Mylotarg)
- Glucarpidase (Voraxaze) FDA approved 1/17/2012
- Goserelin (Zoladex)
H
- Hematopoetic progenitor cells, cord blood (Hemacord) - FDA approved 11/10/2011
- Heparin
- Hydroxyurea (Hydrea)
I
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (PCI-32765) in clinical trials
- Idarubicin (Idamycin)
- Ifosfamide (Ifex)
- Imatinib (Gleevec)
- Ipilimumab (Yervoy)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- IPH 2101 (Anti-KIR) in clinical trials
- Irinotecan (Camptosar)
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Ixabepilone (Ixempra)
L
- Lapatinib (Tykerb)
- Lenalidomide (Revlimid)
- Lepirudin (Refludan)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Lomustine (Ceenu)
M
- Mechlorethamine (Mustargen)
- Melphalan (Alkeran)
- Mercaptopurine (Purinethol)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- Mycophenolate mofetil (CellCept)
N
- Nelarabine (Arranon)
- Neratinib (HKI-272) in clinical trials
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
O
- Obinutuzumab (GA101) in clinical trials
- Octreotide (Sandostatin)
- Ofatumumab (Arzerra)
- Olaparib (AZD-2281) in clinical trials
- Omacetaxine mepesuccinate (Omapro) in clinical trials
- Onartuzumab (MetMAb) in clinical trials
- Oxaliplatin (Eloxatin)
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Pamidronate (Aredia)
- Panitumumab (Vectibix)
- Pazopanib (Votrient)
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (PegIntron)
- Pemetrexed (Alimta)
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pertuzumab (Omnitarg) in clinical trials
- Phytonadione (Vitamin K)
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Pomalidomide (Actimid) in clinical trials
- Ponatinib (AP24534) in clinical trials
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Prednisone (Sterapred)
- Procarbazine (Matulane)
R
- Raloxifene (Evista)
- Regorafenib (BAY 73-4506) in clinical trials
- Rituximab (Rituxan)
- Rivaroxaban (Xarelto) 'FDA approved 7/1/2011
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ruxolitinib (Jakafi) FDA approved 11/16/2011
S
- Sargramostim (Leukine)
- Sipuleucel-T (Provenge)
- Sorafenib (Nexavar)
- Streptozocin (Zanosar)
- Sunitinib (Sutent)
T
- Tacrolimus (Prograf)
- Tamoxifen (Nolvadex)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Thioplex)
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trastuzumab (Herceptin)
- Trastuzumab emtansine (T-DM1) in clinical trials
- Tretinoin (Vesanoid)
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Triptorelin (Trelstar LA)
U
V
- Valrubicin (Valstar)
- Vandetanib (Caprelsa) FDA approved 4/6/2011
- Vemurafenib (Zelboraf) FDA approved 8/17/2011
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo) in clinical trials
- Vindesine (Eldisine)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge) FDA approved 1/30/2012
- Von Willebrand Factor and factor VIII complex, human
- Vorinostat (Zolinza)
W
Z
Reference
- Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article - with chemotherapy sequencing chart